The clinical significance of the receptor activity is unknown.
The clinical significance of treatment of peripheral and central sensitization is unknown.
Rapid Migraine Relief
- The majority of MIGRANAL patients experienced relief within 2 hours2,3*
- 27% considered their migraine resolved as early as 30 minutes after treatment3*
- In a second study, 47% of MIGRANAL patients and 33% of placebo-treated patients had a headache response at 2 hours post-treatment (P>.05). At 4 hours, headache response rates were 56% for MIGRANAL, 35% for placebo (P<.01)2
- Lower incidence of migraine-associated nausea, photophobia, and phonophobia in susceptible patients at 4 hours following administration of MIGRANAL compared with placebo (P<.05)2,3
Long-Lasting Migraine Relief
- 86% experienced lasting relief for 24 hours (n=73, P=.05), compared with 67% of patients on placebo who also experienced symptom relief at 4 hours (n=27)3*
- More than half of MIGRANAL patients did not require additional treatment2
A Well-Established Safety Profile
Please see full Prescribing Information for additional less frequent Adverse Events.
Low Discontinuation Rate
- 1.4% of patients in clinical trials discontinued use because of adverse events (N=1796)2
- Primary causes for discontinuation included rhinitis (n=13), dizziness (n=2), and facial edema (n=2)2
Cardiovascular Adverse Events Are Not Common
- Edema, palpitation, and tachycardia occurred infrequently (occurring in 1/100 to 1/1000 patients)2
- Hypotension, peripheral ischemia, and angina were rare (occurring in fewer than 1/1000 patients)2
- No fatalities due to cardiac events were reported during clinical studies or foreign post-marketing experience2